Business
Director/PDMR Shareholding - ESPP
On August 3, 2026, AOTI, Inc. reported that its Chief Executive Officer, Chief Financial Officer, and Chief Operating Officer purchased a total of 2,766 common shares through the company's Employee Share Purchase Plan at a price of £0.975p per share. Following these transactions, the resultant shareholdings for these individuals are 6,788,972, 406,460, and 1,181,827 shares respectively, representing 6.38%, 0.38%, and 1.11% of the issued share capital. These purchases were made via CSC Global on the London Stock Exchange. Disclaimer*
About this update from Aoti, Inc.
4 August 2026 AOTI INC. (the "Company") Directors'/PDMR Shareholding - Employee Share Purchase Plan The Company was informed on 3 August 2026, that the following purchases of AOTI, Inc. common shares were made by CSC Global 1 on 3 August 2026 on behalf of certain of the Company's persons discharging managerial responsibilities ("PDMR") pursuant to the Company's Employee Share Purchase Plan ("ESPP"). Under the ESPP, participating employees make regular payroll contributions which are used to acquire shares in the Company. Further information regarding the ESPP can be found in the announcement of 1 May 2026. 1 CSC Global operates through CSC Employee Benefit Trustee (Jersey) Limited and CSC Employee Benefit Services (Jersey) Limited 1 Details of the person discharging managerial responsibilities / person closely associated a) Name Mike Griffiths Jayesh Pankhania Anthony Moffatt 2 Reason for the notification a) Position/status 1. Chief Executive Officer 2. Chief Financial Officer 3. Chief Operating Officer b) Initial notification /Amendment Initial notification 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name AOTI Inc. b) LEI 213800ZGCNDSTWIRK687 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the financial instrument, type of instrument Identification code Common shares of $0.00001 each ISIN: US03690C1027 b) Nature of the transaction Purchase of common shares by the Trustee of the Employee Share Purchase Plan c) Price(s) and volume(s) Price(s) Volume(s) Resultant shareholding post purchase Resultant % of ISC post purchase 1. £0.975p 2. £0.975p 3. £0.975p 918 921 927 6,788,972 406,460 1,181,827 6.38% 0.38% 1.11% d) Aggregated information - Aggregated volume - Price NA NA e) Date of the transaction 3 August 2026 f) Place of the transaction London Stock Exchange END AOTI, INC. Dr. Mike Griffiths, Chief Executive Officer Jayesh Pankhania, Chief Financial Officer +44 (0)20 3727 1000 [email protected] Peel Hunt LLP (Nominated Adviser and Joint Broker) Dr. Christopher Golden, James Steel +44 (0)20 7418 8900 Panmure Liberum Limited (Joint Broker) Emma Earl, Will Goode, Mark Rogers Rupert Dearden +44 (0)20 3100 2000 FTI Consulting (Financial PR & IR) Ben Atwell, Simon Conway, Natalie Garland-Collins +44 (0)20 3727 1000 [email protected] ABOUT AOTI, INC. AOTI, INC. was founded in 2006 and is based in Oceanside, California, US and Galway, Ireland, providing innovative solutions to resolve severe and chronic wounds worldwide. Its products reduce healthcare costs and improve the quality of life for patients with these debilitating conditions. The Company's patented non-invasive Topical Wound Oxygen (TWO 2 ® ) therapy has demonstrated in differentiating, robust, double-blinded randomized controlled trials (RCT) and real-world evidence (RWE) studies to more-durably reduce the recurrence of Diabetic Foot Ulcers (DFUs), resulting in an unprecedented 88 per cent reduction in hospitalizations and 71 per cent. reduction in amputations over 12 months. TWO 2 ® therapy can be administered by the patient at home, improving access to care and enhancing treatment compliance. TWO 2 ® therapy has received regulatory clearance from the US (FDA), Europe (CE Mark), UK (MHRA), Health Canada, the Chinese National Medical Products Administration, Australia (TGA) and in Saudi Arabia. TWO 2 ® therapy has also recently received positive coverage recommendations from the Federal Joint Committee (G-BA) in Germany and National Institute for Health and Care Excellence (NICE) in the United Kingdom. Also see www.aotinc.net